SCHEMBL22609234

SCHEMBL22609234

CCOC(=O)c1nnc(Cl)cc1Nc1ccc(F)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.49
▸ LMNA P02545 2/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ SYK P43405 1/20 0.48
▸ MAPT P10636 4/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ CASP3 P42574 1/20 0.47
▸ TRPV1 Q8NER1 1/20 0.47
▸ SENP7 Q9BQF6 1/20 0.47
▸ TP53 P04637 2/20 0.46
▸ POLB P06746 1/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ HPGD P15428 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ ILK Q13418 1/20 0.43
▸ THRB P10828 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23486571 0.87 ILK (0.56) ALDH1A1LMNASYKMAPTMEN1
SCHEMBL15091224 0.83 SYK (0.69) ALDH1A1LMNASYKMAPTMEN1
SCHEMBL22609263 0.81 LMNA (0.50) ALDH1A1LMNAKDM4EMAPTMEN1
SCHEMBL15679619 0.80 ALDH1A1 (0.47) ALDH1A1LMNASYKMAPTMEN1
SCHEMBL15091096 0.79 SYK (0.56) ALDH1A1LMNAKDM4ESYKMAPT
SCHEMBL28359257 0.79 ALDH1A1 (0.47) ALDH1A1LMNAKDM4ESYKMAPT
SCHEMBL29922643 0.79 ALDH1A1 (0.47) ALDH1A1LMNAKDM4ESYKMAPT
SCHEMBL15091278 0.79 SYK (0.46) ALDH1A1KDM4ESYKMAPTMEN1
SCHEMBL15650724 0.77 MEN1 (0.53) ALDH1A1LMNAKDM4ESYKMAPT
SCHEMBL5545753 0.76 LMNA (0.46) ALDH1A1LMNAKDM4EMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF ORFAN BIOTECH SL (ES) 2021-06-10 — — US disclosed
EP-3731840-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF Orfan Biotech Inc. (US) 2020-11-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF PNPO, XDH, GLS ALDH1A1 149/4885LMNA 3881/4885KDM4E 3616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback